MTX110 is a reformulation of Panobinostat, which is an oral medication approved to treat multiple myeloma. In the test tube, it worked great against brain tumors (actually tested as the most promising anticancer agent of all 84 drugs tested) but unfortunately it doesn't cross the blood brain barrier well. Midatech Pharma reformulated it so that it could be injected directly into the tumor using CED (Convection Enhanced Delivery). There are ongoing trials using it for DIPG and Meduloblastoma. This is the first time it is being used for recurrent Glioblastoma.